Global Penny Stocks To Watch In September 2026

As global markets navigate a mix of rising interest rates and fluctuating oil prices, investors are exploring diverse opportunities beyond the traditional blue-chip stocks. Penny stocks, often representing smaller or newer companies, remain an intriguing area for those seeking potential growth at lower price points. Despite being considered a somewhat outdated term, penny stocks continue to offer unique opportunities for investors who focus on strong financials and fundamentals. In this article, we explore three penny stocks that stand out as promising candidates with potential for long-term success.

Here we highlight a subset of our preferred stocks from the screener.

Phoenix Group (ADX:PHX)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Phoenix Group Plc, operating through its subsidiaries, offers crypto and cloud mining services across the United Arab Emirates, Oman, CIS countries, Canada, the United States, and internationally with a market cap of AED3.56 billion.

Operations: Phoenix Group's revenue is primarily generated from its data processing segment, amounting to $103.23 million.

Market Cap: AED3.56B

Phoenix Group Plc has experienced a volatile share price and was recently removed from the FTSE All-World Index, reflecting potential investor concerns. Despite trading significantly below its estimated fair value, the company remains unprofitable with declining earnings over the past five years. Its net debt to equity ratio is satisfactory at 4.1%, and short-term assets comfortably cover both short and long-term liabilities. However, Phoenix's negative return on equity of -33.2% highlights ongoing profitability challenges despite having an experienced management team in place for an average of 2.7 years. The board's inexperience could be a factor to monitor moving forward.

• Click here and access our complete financial health analysis report to understand the dynamics of Phoenix Group.
• Gain insights into Phoenix Group's historical outcomes by reviewing our past performance report.

Qinghai Spring Medicinal Resources Technology (SHSE:600381)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Qinghai Spring Medicinal Resources Technology Co., Ltd. operates in the medicinal resources sector and has a market cap of approximately CN¥2.37 billion.

Operations: Qinghai Spring Medicinal Resources Technology Co., Ltd. has not reported any specific revenue segments.

Market Cap: CN¥2.37B

Qinghai Spring Medicinal Resources Technology has faced challenges, reporting a net loss of CN¥36.1 million for the first half of 2026, compared to a net income last year. Despite this, the company benefits from experienced management and board members with average tenures of 11.3 and 6.8 years respectively. It maintains a robust financial position with short-term assets exceeding both short-term liabilities (CN¥32.4M) and long-term liabilities (CN¥578K). The firm is debt-free and enjoys a positive cash flow that supports an over three-year runway, indicating financial resilience despite current unprofitability challenges.

• Click here to discover the nuances of Qinghai Spring Medicinal Resources Technology with our detailed analytical financial health report.
• Understand Qinghai Spring Medicinal Resources Technology's track record by examining our performance history report.

Sichuan Hebang Biotechnology (SHSE:603077)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Sichuan Hebang Biotechnology Corporation Limited is engaged in the production of agricultural, chemical, and new material products, with a market cap of CN¥19.24 billion.

Operations: Sichuan Hebang Biotechnology Corporation Limited has not reported specific revenue segments.

Market Cap: CN¥19.24B

Sichuan Hebang Biotechnology Corporation Limited has reported a significant net income increase to CN¥380.16 million for the first half of 2026, despite a decline in sales and revenue compared to the previous year. The company's financial health is supported by short-term assets of CN¥13.1 billion, which comfortably cover both its short-term (CN¥2.7 billion) and long-term liabilities (CN¥7.6 billion). While currently unprofitable with negative return on equity, its interest payments are well covered by EBIT at 5.3 times coverage, indicating some operational stability amidst challenges in profitability and increased debt levels over time.

• Dive into the specifics of Sichuan Hebang Biotechnology here with our thorough balance sheet health report.
• Review our historical performance report to gain insights into Sichuan Hebang Biotechnology's track record.

Make It Happen

• Click this link to deep-dive into the 3,606 companies within our Global Penny Stocks screener.
• Looking For Alternative Opportunities? Trump's oil boom is here — pipelines are primed to profit. Discover the 80 US stocks riding the wave.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com